KIMBERLY SNYDER: Open Payments
NPI 1265416341 · RICHMOND, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$781 in 41 payments from 16 companies in 2025. Trend: 2023 $612 · 2024 $684 · 2025 $781
Food & beverage: $731Long term medical supply or device loan: $50
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $150 |
| Astellas Pharma US Inc | 5 | $109 |
| Teva Pharmaceuticals USA, Inc. | 4 | $90 |
| Lundbeck LLC | 4 | $81 |
| Abbott Laboratories | 2 | $69 |
| Novo Nordisk Inc | 2 | $40 |
| Neurocrine BioSciences, Inc. | 2 | $38 |
| Axsome Therapeutics, Inc. | 2 | $37 |
| Amgen Inc. | 2 | $37 |
| Eisai Inc. | 2 | $32 |
Products named: CAPLYTA, Veozah, AUSTEDO XR, REXULTI, FREESTYLE INSULINX, INGREZZA, Auvelity, EVENITY.
Industry payments across IN — which companies pay providers there.
